Alpha Or Leukocyte Patents (Class 424/85.7)
-
Patent number: 11666698Abstract: A fluid delivery device comprises a fluid reservoir for containing medicament. The fluid reservoir is sealed proximate one end with a sliding seal piston. A delivery path is configured to fluidly couple the fluid reservoir and a patient wearing the fluid delivery device. A basal engine mechanism is configured to directly or indirectly move the sliding seal piston in the fluid reservoir at a controlled basal rate. A bolus mechanism configured to move the basal engine relative to the fluid reservoir and directly or indirectly move the sliding seal piston in the fluid reservoir a discrete bolus amount at a time.Type: GrantFiled: July 28, 2020Date of Patent: June 6, 2023Assignee: Mannkind CorporationInventor: Robert R. Gonnelli
-
Patent number: 11560597Abstract: The invention provides a method of determining the epigenetic chromosome interactions which are relevant to a prognostic companion epigenetic test for cancer.Type: GrantFiled: November 30, 2017Date of Patent: January 24, 2023Assignee: Oxford BioDynamics, PLCInventors: Francis Hector Grand, Aroul Selvam Ramadass, Alexandre Akoulitchev, Ewan Hunter
-
Patent number: 11547743Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.Type: GrantFiled: April 24, 2015Date of Patent: January 10, 2023Assignee: Eisai R&D Management Co., Ltd.Inventors: Ryo Ohori, Kanta Horie
-
Patent number: 11534477Abstract: This invention discloses certain methods of treating acute pancreatitis and inflammatory pancreatic disease or condition. The disclosed peptides and analogs can significantly lower the elevated blood amylase and lipase levels caused by acute pancreatitis and pancreatic inflammation, reduce the degree of injury observed in pancreatic histopathology caused by pancreatitis, and significantly lower the mortality rate of acute pancreatitis.Type: GrantFiled: September 3, 2020Date of Patent: December 27, 2022Assignee: SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD.Inventors: Liping Liu, Ru Bai
-
Patent number: 11446358Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.Type: GrantFiled: April 24, 2015Date of Patent: September 20, 2022Assignee: Eisai R&D Management Co., Ltd.Inventors: Ryo Ohori, Kanta Horie
-
Patent number: 11324805Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.Type: GrantFiled: April 24, 2015Date of Patent: May 10, 2022Assignee: Eisai R&D Management Co., Ltd.Inventors: Ryo Ohori, Kanta Horie
-
Patent number: 11241402Abstract: Methods for treating or preventing liver fibrosis in a subject by administering to the subject a therapeutically effective amount of 3-bromopyruvate (3-BrPA) are provided. In addition, methods for promoting the reversal of an activated hepatic stellate cell (HSC) to an inactivated HSC by contacting the activated HSC with at least one 3-bromopyruvate (3-BrPA) molecule are also provided.Type: GrantFiled: July 17, 2020Date of Patent: February 8, 2022Assignee: The Johns Hopkins UniversityInventors: Shanmugasundaram Ganapathy-Kanniappan, Surojit Sur, Bert Vogelstein, Kenneth W. Kinzler, Jean-Francois Geschwind
-
Polypeptide derived from CAP1 and pharmaceutical composition comprising same as effective ingredient
Patent number: 11091515Abstract: The present invention relates to a polypeptide derived from CAP1 and a pharmaceutical composition comprising the same as an effective ingredient and, more particularly, to a peptide including the amino acid sequence of SEQ ID NO: 1, any 0 to 20 amino acid residues added to the N terminus thereof, and any 0 to 75 amino acid residues added to the C terminus thereof, and a pharmaceutical composition comprising the peptide as an effective ingredient for the prevention and alleviation of inflammatory diseases, the inhibition of cancer and cancer metastasis, the prevention and alleviation of diabetes, the prevention and alleviation of arteriosclerosis or cardiovascular diseases, and the prevention and alleviation of heart failure.Type: GrantFiled: January 31, 2018Date of Patent: August 17, 2021Assignee: SEOUL NATIONAL UNIVERSITY HOSPITALInventors: Hyo Soo Kim, Hyun Duk Jang, Sang Eun Lee -
Patent number: 11071755Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.Type: GrantFiled: June 15, 2020Date of Patent: July 27, 2021Assignee: CRISPR Therapeutics AGInventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
-
Patent number: 10981986Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.Type: GrantFiled: March 2, 2017Date of Patent: April 20, 2021Assignee: Teva Pharmaceuticals Australia Pty LtdInventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
-
Patent number: 10940161Abstract: Methods and compositions for modulating repeat non-ATG protein (RAN protein) translation are provided. In some aspects, the disclosure relates to methods for treating a subject having a disease associated with RAN protein translation by administering the subject a modulator of eIF3 or an eIF3 subunit, or an antibody that bind to a RAN protein.Type: GrantFiled: April 4, 2017Date of Patent: March 9, 2021Assignee: University of Florida Research Foundation, IncorporatedInventors: Laura Ranum, Fatma Ayhan, Tao Zu
-
Patent number: 10899788Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein in A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Compound, and methods of using the Cyclic Phosphate Substituted Nucleoside Compounds for treating or preventing HCV infection in a patient.Type: GrantFiled: June 20, 2017Date of Patent: January 26, 2021Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLCInventors: Stephane Bogen, David Dukhan, Guillaume Brandt, Claire Pierra Rouviere, Cyril B. Dousson, Francois-Rene Alexandre
-
Patent number: 10793554Abstract: The present disclosure reports solid forms of (4-(2-fluoro-4-(1-methyl-1H- benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone:Type: GrantFiled: October 29, 2019Date of Patent: October 6, 2020Assignee: Forma Therapeutics, Inc.Inventors: George P. Luke, Stephen Hubbs, Matthew W. Martin, Robert Wenslow, Yawei Shi, Jun Huang
-
Patent number: 10745398Abstract: The invention relates to novel compounds of the formula (I) in which R1, R2, R3, A1, V, X and n have the meanings given above, to their use as acaricides and/or insecticides for controlling animal pests and to processes and intermediates for their preparation.Type: GrantFiled: September 23, 2016Date of Patent: August 18, 2020Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFTInventors: David Wilcke, Rüdiger Fischer, Dominik Hager, Nina Kausch-Busies, Laura Hoffmeister, Kerstin Ilg, Ulrich Görgens, Daniela Portz, Andreas Turberg
-
Patent number: 10723762Abstract: For the removal of high molecular weight compounds from recombinantly produced polypeptides generally chromatographic methods are employed. It has been found that underivatized controlled pore glass (uCPG) selectively binds high molecular weight compounds present in a solution. The purified polypeptide can be recovered e.g. from the flow through of a chromatography column containing uCPG as chromatography material. It has been found that this effect is pronounced at a pH value of about 4 to 6 in buffered solutions. With approximately 100 m2 to 150 m2 uCPG surface per g of polypeptide almost 80% to 95% of the high molecular weight compounds are removed with a yield of 80% to 90% of polypeptide.Type: GrantFiled: April 13, 2017Date of Patent: July 28, 2020Assignee: Hoffman-La Roche Inc.Inventors: Stefan Hepbildikler, Wolfgang Kuhne, Eva Rosenberg, Gerhard Winter
-
Patent number: 10688083Abstract: Disclosed herein are methods for use of R-chloroquine or clemizole or combinations of R-chloroquine and clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory? conditions, treating liver cancer or reducing the risk of developing liver cancer in a subject. Uses also include methods of treating non-alcoholic steatohepatitis in a subject.Type: GrantFiled: June 30, 2016Date of Patent: June 23, 2020Assignee: Eiger Group International, Inc.Inventors: Jeffrey S. Glenn, Edward A. Pham
-
Patent number: 10624931Abstract: Disclosed are compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are compositions comprising a previously cryopreserved umbilical tissue, wherein after cryopreservation and subsequent thawing the umbilical tissue comprises: a) viable cells native to the umbilical tissue; b) tissue integrity of native umbilical tissue; c) one or more growth factors that are native to the umbilical tissue; and d) depleted amounts of one or more types of functional immunogenic cells. Disclosed are methods of producing compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are methods of treating damaged tissue comprising administering to the site of the damaged tissue compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels.Type: GrantFiled: September 23, 2016Date of Patent: April 21, 2020Assignee: Osiris Therapeutics, Inc.Inventors: Alla Danilkovitch, Yi Duan-Arnold, Matthew Moorman, Anne Lerch, Jin-Qiang Kuang
-
Patent number: 10610569Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.Type: GrantFiled: April 24, 2015Date of Patent: April 7, 2020Assignee: Eisai R&D Management Co., Ltd.Inventors: Ryo Ohori, Kanta Horie
-
Patent number: 10562929Abstract: A cyclic dinucleotide compound of Formula (I): wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.Type: GrantFiled: June 12, 2018Date of Patent: February 18, 2020Assignee: KAYLA THERAPEUTICSInventors: Fabienne Vernejoul, Gerard Tiraby, Thierry Lioux
-
Patent number: 10544199Abstract: The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon ? 2b (IFN?2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN?2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN?2b.Type: GrantFiled: October 23, 2015Date of Patent: January 28, 2020Assignee: Teva Pharmaceuticals Australia Pty LtdInventors: Collette Behrens, Anthony Doyle, Adam Clarke, Matthew Pollard, Teresa Domagala
-
Patent number: 10537612Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.Type: GrantFiled: April 24, 2015Date of Patent: January 21, 2020Assignee: Eisai R&D Management Co., Ltd.Inventors: Ryo Ohori, Kanta Horie
-
Patent number: 10519239Abstract: Agents that inhibit the dimerization of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7. The use of such agents to inhibit a biological, physiological and/or pathological process that involves prototypic galectin dimerization, for example for the inhibition of galectin-7-mediated apoptosis and the treatment of galectin-7-expressing cancers, is also described.Type: GrantFiled: May 25, 2016Date of Patent: December 31, 2019Assignee: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: David Chatenet, Nicolas Doucet, Yves St-Pierre, Maria-Claudia Vladoiu
-
Patent number: 10344019Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: July 30, 2015Date of Patent: July 9, 2019Assignee: Gilead Pharmasset LLCInventors: Elizabeth M. Bacon, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, Evan S. Krygowski, John O. Link, James G. Taylor, Chinh Tran, Teresa Alejandra Trejo Martin, Zheng-Yu Yang, Sheila M. Zipfel
-
Patent number: 10337011Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Fibroblast growth factor 21 (FGF21), in particular, by targeting natural antisense polynucleotides of Fibroblast growth factor 21 (FGF21). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of FGF21.Type: GrantFiled: August 23, 2017Date of Patent: July 2, 2019Assignee: CuRNA, Inc.Inventors: Joseph Collard, Olga Khorkova Sherman
-
Patent number: 10329353Abstract: The present invention includes the discovery of cell-surface vimentin as a novel biomarker to detect and isolate mesenchymal and epithelial-mesenchymal transformed circulating tumor cells from blood of cancer patients. In addition, an antibody specific for the detection of cell-surface vimentin on circulating tumor cells and the use the antibody to detect, enumerate, and isolate CTC are provided.Type: GrantFiled: March 5, 2014Date of Patent: June 25, 2019Assignee: Board of Regents, The University of Texas SystemInventors: Arun Satelli, Shulin Li
-
Patent number: 10280421Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Interferon Regulatory Factor 8 (IRF8), in particular, by targeting natural antisense polynucleotides of Interferon Regulatory Factor 8 (IRF8). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IRF8.Type: GrantFiled: October 31, 2017Date of Patent: May 7, 2019Assignee: CuRNA, Inc.Inventors: Joseph Collard, Olga Khorkova Sherman
-
Patent number: 10238680Abstract: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.Type: GrantFiled: November 30, 2015Date of Patent: March 26, 2019Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Benjamin Alexander Mayes, Adel M. Moussa, Cyril B. Dousson, Gilles Gosselin, Claire Pierra, David Dukhan
-
Patent number: 10233170Abstract: The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-? superfamily such as Nodal or Activin.Type: GrantFiled: April 2, 2015Date of Patent: March 19, 2019Assignee: Rigel Pharmaceuticals, Inc.Inventors: Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Donald Payan, Marina Gelman, Todd Kinsella
-
Patent number: 10130612Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.Type: GrantFiled: December 11, 2017Date of Patent: November 20, 2018Assignee: GenfitInventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
-
Patent number: 10052293Abstract: A Curcumin infused milk beverage composition comprising 0.05% to 0.15% alkalized Curcumin, standardized milk with fat, sugar and stabilizing agents, wherein the pH of resultant composition is maintained at 6.8.Type: GrantFiled: August 31, 2016Date of Patent: August 21, 2018Inventor: Srikumar Misra
-
Patent number: 9931413Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-?2b.Type: GrantFiled: October 12, 2016Date of Patent: April 3, 2018Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Patent number: 9907796Abstract: Novel compounds and their synthesis are described. Methods for using these compounds in the prevention or treatment of cancer, a bacterial infection or a viral infection in a subject are also described.Type: GrantFiled: September 15, 2016Date of Patent: March 6, 2018Assignee: INHIBIKASE THERAPEUTICS, INC.Inventors: Rhushikesh Chandrabhan Deokar, Sundeep Dugar, Dinesh Mahajan, Milton Henry Werner
-
Patent number: 9775831Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.Type: GrantFiled: July 15, 2014Date of Patent: October 3, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Mark G. Saulnier, David B. Frennesson, Makonen Belema
-
Patent number: 9669105Abstract: Disclosed is a liquid formulation in which a long-acting INF? conjugate that has improved in vivo duration and stability can be stored stably for a long period of time. It comprises a stabilizer comprising a buffer, a sugar alcohol, a non-ionic surfactant and an isotonic agent. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting INF? conjugates.Type: GrantFiled: October 26, 2011Date of Patent: June 6, 2017Assignee: HANMI SCIENCE CO., LTD.Inventors: Dae Seong Im, Jae Min Lee, Jong Soo Lee, Sung Min Bae, Se Chang Kwon
-
Patent number: 9657302Abstract: A plastid transformation vector for a stably transforming a plastid genome is provided. The vector includes, as operably-linked components, a first flanking sequence, a DNA sequence coding for a therapeutic human IFN, which is capable of expression in the plastid and a second flanking sequence. The invention also provides isolated and purified IFN, wherein the IFN is configured in a monomeric or multimeric form and is a structural equivalent to orally administered human IFN. Also provided are methods for variable-expressing biopharmaceutical proteins in plants suitable for mammal consumption. The method includes integrating a plastid transformation vector into a plastid genome of a plant cell; growing the plant cell to express a biopharmaceutical protein, such as therapeutic human interferon IFN. Also disclosed are plants transformed with the aforementioned vectors, and the progeny thereof. Also, disclosed is the IFN, which is IFN?2b.Type: GrantFiled: November 10, 2014Date of Patent: May 23, 2017Assignee: The Trustees of the University of PennsylvaniaInventor: Henry Daniell
-
Patent number: 9644015Abstract: A codon optimized nucleic acid sequence for Interferon Alpha-2a is provided which can be used for expression of Interferon Alpha-2a in E. Coli.Type: GrantFiled: March 28, 2013Date of Patent: May 9, 2017Assignee: BIOGENOMICS LIMITEDInventors: Archana Rajesh Krishnan, Sanjay Madhukar Sonar, Damodar Krishnabahadur Thappa
-
Patent number: 9617547Abstract: Problem The purpose of the present invention is to provide: a stereo isomer of a novel CpG oligonucleotide, which has excellent stability; and a CpG oligonucleotide which has a capability of producing interferon-? (IFN?). Solution The present invention relates to an oligonucleotide which contains two to four sequences each represented by the formula 5?-X1X2CpGX3X4-3? (formula (I)) and has a length of 14 to 32 nucleotides. In formula (I), CpG represents a non-methylated CpG residue having a phosphate skeleton modification, X1X2 represents any one of AA, AT, GA and GT, and X3X4 represents any one of TT, AT, AC and CG. The oligonucleotide has at least one phosphate skeleton modification at an S-form stereoisomer located at a site other than the CpG.Type: GrantFiled: July 12, 2013Date of Patent: April 11, 2017Assignees: Shin Nippon Biomedical Laboratories, Ltd., WAVE LIFE SCIENCES JAPANInventor: Takefumi Gemba
-
Patent number: 9611479Abstract: Disclosed are bridged nucleosides and nucleotides. The nucleosides of the present invention have a 2?,4?-bridged structure and are represented by formula I below: An oligonucleotide containing a 2?,4?-bridged artificial nucleotide of the present invention has a binding affinity for single-stranded RNA comparable to that of known 2?,4?-BNA/LNA and higher nuclease resistance than LNA. In particular, since the oligonucleotide has a much higher binding affinity for single-stranded RNA than S-oligo, it is expected that the oligonucleotide is applicable to nucleic acid drugs.Type: GrantFiled: February 17, 2015Date of Patent: April 4, 2017Assignee: Osaka UniversityInventors: Satoshi Obika, Takao Yamaguchi, Masahiko Horiba, Reiko Waki
-
Patent number: 9573939Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.Type: GrantFiled: August 16, 2012Date of Patent: February 21, 2017Assignees: Merck Sharp & Dohme Corp., MSD Italia SRLInventors: Casey C. McComas, Nigel J. Liverton, Joerg Habermann, Uwe Koch, Frank Narjes, Peng Li, Xuanjia Peng, Richard Soll, Hao Wu, Anandan Palani, Xing Dai, Hong Liu, Shuwen He, Qun Dang
-
Patent number: 9573952Abstract: The present invention provides methods of preparing 4-amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one and related compounds.Type: GrantFiled: September 14, 2015Date of Patent: February 21, 2017Assignee: Gilead Sciences, Inc.Inventors: Darin Allen, Brandon Heath Brown, Jessica Jade Chao, Randall L. Halcomb, Paul Hrvatin, Ryan McFadden, Paul Roethle, Erwina Rudio, Hong Yang, Richard Hung Chiu Yu
-
Patent number: 9555039Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.Type: GrantFiled: September 2, 2011Date of Patent: January 31, 2017Assignee: Forma TM, LLC.Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Bingsong Han, Judith D. Kuntz, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
-
Patent number: 9534033Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).Type: GrantFiled: August 30, 2013Date of Patent: January 3, 2017Assignee: The Regents of the University of CaliforniaInventors: Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
-
Patent number: 9339541Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001: where PD, Base, RA and RB are as provided herein. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: GrantFiled: March 3, 2014Date of Patent: May 17, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Cyril B. Dousson, Benjamin Alexander Mayes, David Dukhan, Adel M. Moussa, Alistair James Stewart
-
Patent number: 9284292Abstract: The present invention discloses a new class of compounds that exhibit an inhibitory effect on influenza virus type A and B, which may or may not be resistant to other drugs, as well as on other types of viruses, such as flavivirus but also on protozoa and other micro-organisms, their preparation methods, pharmaceutical formulations containing them and their use as medicinal products for the treatment of various conditions caused by particular microorganisms, including viruses, bacteria and protozoa, which affect animal and human health.Type: GrantFiled: November 25, 2010Date of Patent: March 15, 2016Assignee: THERAPICON S.R.L.Inventors: Paolo Alberto Veronesi, Pablo E. A. Rodriguez, Anna Maria Veronesi, Emanuela Peschechera
-
Patent number: 9278090Abstract: Disclosed is a method of preventing the development of mucositis in a subject undergoing radiation therapy or chemotherapy for a disease in need thereof comprising administering an effective amount of a mammalian target of rapamycin (mTOR) inhibitor, such as rapamycin, to the subject. Further disclosed is a method of increasing the lifespan of a normal oral keratinocyte and/or reducing oxidative stress in a normal epithelial cell, wherein the method comprises administering an effective amount of an mTOR inhibitor to a subject undergoing radiation therapy or chemotherapy for a disease in need thereof.Type: GrantFiled: March 13, 2013Date of Patent: March 8, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: J. Silvio Gutkind, Ramiro Iglesias-Bartolome, Vyomesh Patel, Ana p. Cotrim, Alfredo Molinolo, James B. Mitchell
-
Patent number: 9273133Abstract: Compositions and methods for treating fibrotic diseases are provided.Type: GrantFiled: December 4, 2009Date of Patent: March 1, 2016Assignees: Lankenau Institute for Medical Research, Thomas Jefferson UniversityInventors: Allyn Sue Menko, Mindy George-Weinstein, Janice L. Walker, Jacquelyn Gerhart
-
Patent number: 9249174Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.Type: GrantFiled: December 19, 2013Date of Patent: February 2, 2016Assignee: Alios BioPharma, Inc.Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith
-
Patent number: 9243022Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.Type: GrantFiled: December 19, 2013Date of Patent: January 26, 2016Assignee: Alios BioPharma, Inc.Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith
-
Patent number: 9084806Abstract: The present invention relates to an amphiphilic polymer whose property and structure can change under hypoxic conditions, and to nanoparticles formed by self-assembly of the amphiphilic polymer. The hypoxia-responsive nanoparticles according to the present invention release a drug selectively under hypoxic conditions. Thus, the nanoparticles can be used for the selective diagnosis and treatment for diseases that are accompanied by hypoxia. Particularly, the nanoparticles can release a drug only to a targeted tumor in cancer therapy, and thus have minimized side effects and maximized therapeutic effects.Type: GrantFiled: November 12, 2013Date of Patent: July 21, 2015Assignee: Research & Business Foundation Sungkyunkwan UniversityInventor: Jae Hyung Park
-
Patent number: 9072778Abstract: The present invention relates to methods and compositions for treating diseases. More specifically, the present invention relates to the administration of multiple drugs as part of a treatment of disease. Specific embodiments of the invention relate to a treatment regimen for neuroblastomas and other N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors, comprising administering multiple therapeutic compounds like DFMO, SAM486A, a verinoid and a cytotoxic drug and placing the patient on a low polyamine diet and/or providing the patient with a polyamine limiting dietary supplement.Type: GrantFiled: December 20, 2006Date of Patent: July 7, 2015Assignee: UNIVERSITY OF HAWAIIInventor: Andre S. Bachmann